An approach to addressing subpopulation considerations in systematic reviews: the experience of reviewers supporting the U.S. Preventive Services Task Force by Whitlock, Evelyn P et al.
COMMENTARY Open Access
An approach to addressing subpopulation
considerations in systematic reviews: the
experience of reviewers supporting the U.S.
Preventive Services Task Force
Evelyn P. Whitlock1, Michelle Eder2* , Jamie H. Thompson2, Daniel E. Jonas3, Corinne V. Evans2,
Janelle M. Guirguis-Blake4 and Jennifer S. Lin2
Abstract
Background: Guideline developers and other users of systematic reviews need information about whether a
medical or preventive intervention is likely to benefit or harm some patients more (or less) than the average in
order to make clinical practice recommendations tailored to these populations. However, guidance is lacking on
how to include patient subpopulation considerations into the systematic reviews upon which guidelines are
often based. In this article, we describe methods developed to consistently consider the evidence for relevant
subpopulations in systematic reviews conducted to support primary care clinical preventive service recommendations
made by the U.S. Preventive Services Task Force (USPSTF).
Proposed approach: Our approach is grounded in our experience conducting systematic reviews for the USPSTF and
informed by a review of existing guidance on subgroup analysis and subpopulation issues. We developed and refined
our approach based on feedback from the Subpopulation Workgroup of the USPSTF and pilot testing on reviews
being conducted for the USPSTF. This paper provides processes and tools for incorporating evidence-based
identification of important sources of potential heterogeneity of intervention effects into all phases of systematic
reviews. Key components of our proposed approach include targeted literature searches and key informant
interviews to identify the most important subpopulations a priori during topic scoping, a framework for assessing
the credibility of subgroup analyses reported in studies, and structured investigation of sources of heterogeneity
of intervention effects.
Conclusions: Further testing and evaluation are necessary to refine this proposed approach and demonstrate its
utility to the producers and users of systematic reviews beyond the context of the USPSTF. Gaps in the evidence
on important subpopulations identified by routinely applying this process in systematic reviews will also inform
future research needs.
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Background
The growing focus on patient-centered outcomes in
health care has been accompanied by increasing interest
in targeted, individualized recommendations for clinical
care, including screening, preventive interventions, and
treatment. This is driven in large part by the rising rec-
ognition that medical interventions do not affect all
patients in the same way, a situation referred to as het-
erogeneity of intervention (treatment) effects [1]. Guide-
line developers and other users of systematic reviews
seek information about whether a preventive or medical
intervention is likely to benefit some patients more (or
less) than the average and to understand which patients
are at greatest (or least) risk of intervention-related
harm [2]. As such, there has been a need to develop
methods for dealing with heterogeneity of intervention
effects to help address concerns about the inappropriate
clinical application of average effects and to aid guideline
developers in making recommendations tailored to spe-
cific subpopulations of patients when appropriate. Two
recent surveys of existing practices and published guid-
ance for considering clinical heterogeneity in systematic
reviews found that there is little consensus and limited
clear guidance to support consistent approaches to
this important issue, although these are very much
needed [2, 3].
To this end, we have developed and piloted a process
for including patient subpopulation considerations into
all phases of systematic reviews with two explicit goals:
(1) to provide a consistent, systematic assessment of the
evidence base for specific subpopulations within a given
systematic review and (2) to provide the U.S. Preventive
Services Task Force (USPSTF) with the information ne-
cessary to inform judgments about the appropriateness
of general population versus subpopulation-specific clin-
ical practice recommendations. The approach described
in this paper was developed to provide practical guid-
ance for the consistent application of subpopulation
considerations in systematic reviews conducted by
Evidence-based Practice Centers (EPCs) funded by the
Agency for Healthcare Research and Quality (AHRQ) to
support primary care clinical preventive service recom-
mendations made by the USPSTF.
Background work conducted for this project included
an examination of available information on how major
guideline developers and groups setting standards for
systematic reviews address subgroup analyses and sub-
population issues. We chose ten groups with particular
relevance to primary care preventive services in the USA
or internationally recognized for their well-developed
methods (see Table 1). In November 2015, we reviewed
their websites (and manuals or written procedures,
where available) for descriptions of methods used to
evaluate subgroup-specific evidence and address subpop-
ulation issues.
Based on our 15 years’ experience conducting system-
atic reviews for the USPSTF, and informed by relevant
literature discussing subgroup analysis and subpopula-
tion issues, we developed tools and methods for incorp-
oration of subpopulation considerations into each of
four phases of the systematic review process: (I) topic
scoping and work plan (protocol) development, (II) data
abstraction and critical appraisal, (III) data analysis and
synthesis, and (IV) reporting and interpretation. We pre-
sented these tools and processes to the Subpopulation
Workgroup of the USPSTF and revised our draft
approach based on feedback from workgroup members.
We refined our proposed methods based on pilot testing
Table 1 Summary of subgroup-specific information addressed by select guideline developers and groups setting standards for
systematic reviews
PHASE I Topic scoping and
work plan development
PHASE II Data abstraction
and critical appraisal
PHASE III Data analysis
and synthesis
PHASE IV Reporting
and interpretation
AAFP [42]
AAP [43]
ACOG [44]
ACP [45, 46]
CTFPHC [12] ✓ ✓
CPSTF [47, 48]
Cochrane [7, 11, 49] ✓ ✓ ✓
GRADE [8–10, 20] ✓ ✓ ✓ ✓
IOM [14, 50] ✓ ✓
NICE [13] ✓
AAFP American Academy of Family Physicians, AAP American Academy of Pediatrics, ACOG American Congress of Obstetricians and Gynecologists, ACP American
College of Physicians, CTFPHC Canadian Task Force on Preventive Health Care, CPSTF Community Preventive Services Task Force, Cochrane The Cochrane
Collaboration, GRADE Grading of Recommendations Assessment, Development and Evaluation Working Group, IOM Institute of Medicine, NICE National Institute
for Health and Care Excellence
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the approach on three reviews conducted for the USPSTF:
Aspirin for the Primary Prevention of Cardiovascular
Events, Screening for Lipid Disorders in Adults, and
Screening for Obstructive Sleep Apnea in Adults [4–6].
Main text
Key concepts and definitions
We use the terms “subgroup” and “subpopulation” to
refer to distinct elements, such that “subpopulations”
refer to groups of individuals that are the target of policy
or practice recommendations, and “subgroups” refer to
specific types of analyses undertaken on a subset of par-
ticipants (see Table 2). In the context of systematic re-
views, differences between studies (i.e., heterogeneity)
must be considered to appropriately summarize a body
of evidence, including making decisions about whether
or not to quantitatively combine results [7]. Heterogen-
eity considerations should inform decisions made about
the review scope and methods during protocol develop-
ment, including planned approaches to data abstraction
and data synthesis, as well as final interpretation of
review findings. The set of included studies for a system-
atic review question can differ somewhat or substantially
in dimensions underlying heterogeneity: the populations
studied, the interventions investigated, and the outcomes
measured, as well as in the methods underpinning each
study’s findings. These differences can be understood as
clinical, methodological, and statistical heterogeneity, all
Table 2 Definitions of terminology used
Term Description/definition Example(s)
Subgroup The term “subgroup” describes an analysis of a subset
of participants (e.g., selected set of individuals with
specific patient characteristics within an individual study
or across studies in the case of individual patient data
meta-analyses).
“Subgroup analyses are often performed to identify
characteristics within the study population that are
associated with greater benefit from the intervention,
with no benefit, or even with harm” [37].
Subpopulation The term “subpopulation” describes a specific group
of individuals with common patient characteristics
(e.g., race/ethnicity, age, risk factors) that is the target
of an intervention or a policy recommendation.
“If a subpopulation may not benefit from the therapy,
it is important to identify the subpopulation and
verify this finding in an appropriate clinical trial” [37].
Clinical heterogeneity Variability between studies in the populations enrolled,
the active interventions and comparison interventions
they receive, or selection and timing of measured
outcomes [3, 7].
Patient characteristics
• Socio-demographics
• Baseline risk
Study characteristics
• Intervention
• Comparators
• Outcome measurement
Methodological heterogeneity Variability in study design and conduct that can
lead to differences in measured intervention effects
due to non-comparability or bias [3, 7].
Risk of bias
• Study design
• Study conduct
• Study analysis
Statistical heterogeneity Measured variability in observed intervention effects
between studies that are greater than would be
expected due to chance (random error) [3, 7].
Statistical tests
• I2
• Cochran’s Q test
Within study The term “within study” refers to the framework in
which comparisons or analyses are conducted;
in this case, researchers are examining the variation
or impact of factors (e.g., populations, interventions,
outcomes) within one study or trial.
"In single trials, the comparison [between subgroups]
is always within studies: that is, the two groups of
patients (e.g., the older and younger) or the two
alternative ways of administering the intervention
(e.g., higher and lower doses) were assessed in the
same RCT" [26].
Between study The term “between study” refers to the framework in
which comparisons or analyses are conducted;
in this case, researchers are examining the variation
or impact of factors (e.g., populations, interventions,
outcomes) across multiple studies or trials.
"The inference regarding the effect is, however, limited because
this was a between study rather than a within study
comparison. As a result there are a number of competing
explanations for the observed differences between the
high- and low-dose studies” [26].
Study level The term “study level” is used to describe the unit
of inquiry or data source being considered by
systematic reviewers; in this case, data from a single
study or trial are evaluated.
"The ideal way to study causes of true variation is within
rather than between studies. In most situations however,
we will have to make do with a study level investigation
\and hence need to be careful about adjusting for
potential confounding by artefactual factors such as
study design features" [51].
Body of evidence level The term “body of evidence level” is used to describe
the unit of inquiry or data source being considered
by systematic reviewers; in this case, data from a
group of studies are evaluated.
"Systematic review and guideline authors use this [GRADE]
approach to rate the quality of evidence for each
outcome across studies (i.e., for a body of evidence)" [52].
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of which inform the synthesis of evidence within a sys-
tematic review (see Table 2) [7].
Clinical heterogeneity reflects variation between stud-
ies in the populations enrolled, in the active interven-
tions and comparison interventions they receive, or in
selection and timing of measured outcomes [2]. When
there are variable intervention effects across studies,
investigating how these differences may be related to
effect variation can inform targeting or tailoring
research information to specific populations, situations,
or circumstances. Clinical heterogeneity is the type of
heterogeneity most related to subgroup and subpopula-
tion issues and therefore of major interest to clinical
and policy-level decision-makers [3]. Methodological
heterogeneity reflects differences in study design and
conduct, including risk of bias, across studies in the
systematic review [7]. Methodological heterogeneity
can lead to differences in measured intervention effects,
but these reflect artifacts of the research process rather
than clinically relevant differences. Finally, statistical
heterogeneity is revealed through statistical testing as
to whether measured differences in intervention out-
comes between studies in the body of evidence are
greater than would be expected due to chance (gener-
ally p < 0.05) [2]. The job of the systematic reviewer is
to understand the interrelationships of these factors, to
control for (or investigate) them in assembling and analyz-
ing a body of evidence to answer a particular question,
and to summarize and communicate their implications for
decision-makers.
Existing guidance
Both guideline developers and systematic reviewers
working on behalf of guideline developers have a strong
interest in specifying credible, relevant methods for fairly
and consistently considering subgroup findings from pri-
mary studies and subpopulation differences in interven-
tion effects. To inform our work, we therefore examined
how selected prominent guideline developers or groups
setting standards for systematic reviews address these
two issues. Table 1 summarizes the subgroup-specific
information addressed by selected guideline and review
groups for each phase of a systematic review. Our review
revealed that prominent guideline developers typically
lack detailed information about how to plan and use
subgroup analyses. While some of the review or guide-
line groups addressed the issue of handling subgroup
data conceptually or in detail for a specific aspect of the
systematic review, no group outlined a comprehensive
approach to integrating subgroup considerations and
analyses into all phases of the systematic review process.
GRADE provided the most comprehensive guidance
on inclusion of subgroups in all phases of systematic
reviews and is the only group that addressed credibility
assessment of subgroup analyses [8–10]. The Cochrane
Collaboration Handbook also included guidance on the use
of subgroup analyses in reviews and addressed a priori
selection of a small number of study characteristics for sub-
group analyses that are supported by scientific evidence,
how to analyze subgroup data to investigate heterogeneity,
and interpretation of subgroup analyses, including
caveats such as the potential for bias since subgroup
comparisons are not usually accounted for by the
randomization approach [3, 7]. In their description of
methods for child health reviews, the Cochrane Child
Health team also provides questions regarding age-
based treatment effects to guide the planning of a
priori subgroup analyses [11].
Selected other groups included in our scan (i.e., the
Institute of Medicine (IOM), the National Institute for
Health and Care Excellence (NICE), the Community
Preventive Services Task Force (CPSTF), and the Canadian
Task Force on Preventive Health Care (CTFPHC))
touched briefly on subgroup considerations for one or two
of the systematic review phases. Description of subgroup
methods during review scoping and work plan develop-
ment was generally limited to a series of questions to guide
the inclusion of subgroups [12, 13] or to specifying the
standard that reviewers should describe and justify a priori
any planned subgroup analyses, in the case of the IOM
[14]. Information from these groups on reporting and
interpretation of subgroup findings consisted of a few
elements that should be reported by reviewers (e.g.,
clinical and methodological characteristics of studies)
[7, 14]. Related efforts on equity-focused reviews and
clinical guidelines by the PRISMA-Equity Bellagio
group [15] and NICE [16], respectively, highlight the
importance of addressing health disparities in systematic
reviews. The PRISMA-Equity Bellagio group focuses on
improved reporting in equity-focused systematic reviews,
including items such as presentation of subgroup analyses
[15]. The NICE guideline on addressing equality issues
includes scoping discussions about inequalities in
prevalence, risk factors, or severity and a priori identifi-
cation of relevant subpopulations [16].
The professional society websites we reviewed (i.e.,
American Academy of Family Physicians (AAFP),
American Academy of Pediatrics (AAP), American
Congress of Obstetricians and Gynecologists (ACOG),
American College of Physicians (ACP)) did not include
any information about how subpopulations are considered
in their guidelines or address how subgroup consider-
ations are incorporated in the reviews of the evidence on
which their guidelines are based.
Proposed approach
Below we describe the methods we developed for in-
corporating subpopulation considerations into the four
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major phases of a systematic review: (I) topic scoping
and work plan (protocol) development, (II) data
abstraction and critical appraisal, (III) data analysis
and synthesis, and (IV) reporting and interpretation
(Fig. 1). We developed these approaches primarily to
support our work conducting systematic reviews for
the USPSTF given their need to judge the appropri-
ateness of general population versus subpopulation-
specific clinical practice recommendations. The
process of translating the subpopulation evidence
presented in systematic reviews into clinical practice
recommendations is described in another manuscript
[17]. Below we provide examples for many of our
processes and tools based on our systematic review
experiences with the USPSTF.
Phase I: topic scoping and work plan development
Topic scoping
Decisions about which subpopulations will be investi-
gated in a systematic review should be based on under-
standing of the existing evidence base [18]; therefore,
the first step in exploration of important subpopulations
during topic scoping involves targeted literature searches
informed by clinical consultation as necessary. These
literature searches include:
 How other guideline groups have recently handled
subpopulation considerations for the topic
 How other recent, well-conducted systematic
reviews have handled subpopulation considerations
for the topic
Fig. 1 Major phases of systematic reviews and corresponding subpopulation processes
Whitlock et al. Systematic Reviews  (2017) 6:41 Page 5 of 25
 Data on incidence, prevalence, morbidity, and
mortality for the condition of interest by age, sex,
race/ethnicity, and important topic-specific clinical
characteristics
The collected information is used to identify presump-
tive subpopulations of interest, understand the issues
within the literature related to relevant subpopulations,
and develop a set of questions for key informant inter-
views consisting of two to four clinical and content ex-
perts in the systematic review topic area. Key informant
candidates may include, for example, previous reviewers
for the specific content area, authors of validated risk as-
sessment tools, principal investigators of large trials that
include subgroup analyses, leaders in professional soci-
eties relevant to the clinical topic, or members of clinical
guideline panels. The purpose of conducting key inform-
ant interviews is to learn which subpopulations experts
would be most concerned about being given a general
population screening and/or treatment recommendation,
as opposed to a subpopulation-specific recommendation,
and why.
Key informants can help determine what is known
about sources of heterogeneity of intervention effects
(e.g., prior subgroup analyses, dose-response relation-
ships, or differences in outcomes) and known or concern
about potential subpopulation differences for the topic.
Candidate patient-level variables to define subpopula-
tions include age, sex, race, ethnicity, comorbidities,
baseline disease risk, disease severity or other important
disease features, genetic variants, or psychosocial vari-
ables with a clear scientific rationale as a treatment ef-
fect modifier [19]. Key informant questions can confirm
or query important issues on potential mechanisms of
preventive services heterogeneity within specific subpop-
ulations (e.g., differing baseline risk of disease-related
outcomes, competing risks/limited life expectancy, vary-
ing risk(s) of intervention harm(s), variable responsive-
ness to the preventive intervention, differential impact of
time to benefit or to harm, primary and differing values
for patient-important outcomes). Table 3 shows how
these mechanisms might affect questions about hetero-
geneity for different types of clinical preventive services
to support development of questions for key informants.
Experts can help identify epidemiological data to support
potential mechanisms of heterogeneity as well as validated
risk assessment tools or large multivariable analyses show-
ing the combined impact of potential subgroup factors on
outcomes for the condition of interest. Table 4 provides
sample questions to guide reviewers in developing
topic-specific questions for obtaining feedback from
key informants.
In our experiences with implementing this approach,
we confirmed the value of eliciting expert input into our
subpopulation considerations early in the review process.
These experts can often provide guidance about import-
ant resources (e.g., presentations from relevant profes-
sional society meetings) or ongoing research that would
otherwise take considerable effort to locate. By efficiently
helping us understand the perspectives of clinical and
research experts, we could more quickly focus on sub-
populations with sufficient prior evidence or controversy
to guide our protocol development. We also found that
a conference call format (conducted one-on-one or with
a few individuals) may be more conducive to gathering
detailed expert perspectives with accompanying rationale
and allows for easy clarification of complex statements.
Eliciting expert feedback via email, however, can still
provide valuable information with limited time and
effort expended.
Work plan development
Work plan development for a systematic review
includes drafting an analytic framework, research ques-
tions, and inclusion/exclusion criteria that specify the
logic and scope of the review, including the popula-
tions, interventions, comparators, and outcomes of
interest. An analytic framework is a graphic representa-
tion of linkages between interventions and outcomes
that helps to identify the questions that the review is
addressing [7, 20–22]. The background searches and
key informant interviews described above help deter-
mine whether and how relevant subpopulations will be
incorporated into the analytic framework, research
questions, and inclusion/exclusion criteria that guide
the literature searches, data abstraction, and analysis
processes in later phases of the systematic review.
We developed a summary table to assist reviewers in
presenting the findings from the topic scoping process,
including the key informant interviews, and outlining
recommendations for incorporation of specific subpopu-
lations into the work plan for consideration and
approval by AHRQ and the USPSTF. Table 5 provides
an example of a completed summary table for a review
on aspirin for the primary prevention of cardiovascular
events [5]. The primary purpose of the table was to sup-
port the a priori selection of a limited number of patient
subpopulations to be examined in the systematic review
and to provide the rationale for inclusion of these sub-
populations. The six columns in the table are defined as:
(A) Previous systematic review’s approach: How each
subpopulation of interest was addressed in the
previous systematic review, if at all.
(B) Separate recommendation statement: Whether
the guidance included a separate recommendation
statement for each subpopulation of interest.
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(C) Importance: Initial summary rating of the
importance of each subpopulation relative to others
suggested for inclusion in the systematic review to
inform parsimonious selection.
(D) Rationale: Summary of information that supports
each subpopulation as important and relevant to the
systematic review (e.g., epidemiological trends,
biological plausibility), including how key informant
input supports the rationale for each subpopulation.
(E) Policy context: How recent reviews, meta-analyses,
and clinical practice guidelines address preventive
services recommendations for each identified
subpopulation, including any disagreement across
guidelines and reviews and how key informant input
supports the policy importance of each
subpopulation.
(F) Proposed work plan approach: Whether each
subpopulation is proposed to be one of the a priori
subpopulations for this review, and potential
approaches to including it in the work plan,
including hypothesized direction of effect, impact
on net benefit, and mechanisms of action, if known.
As a result of the application of this process, the
review designated age and sex as the a priori subgroup
analyses and subpopulations of highest importance for
the systematic review to update evidence addressing
both benefits and harms [5]. We listed other cardiovas-
cular disease (CVD) risk factors (including smoking, dia-
betes, blood pressure, and peripheral artery disease
(PAD)) as important to examine for potential effect
modification in terms of aspirin’s benefits, in particular,
and listed selected medications, including selective sero-
tonin reuptake inhibitors and non-aspirin non-steroidal
anti-inflammatory drugs, as modifiers of potential harms
of treatment only. A focused, a priori approach can be
criticized for not being comprehensive; however, it con-
forms to guidance for parsimonious selection of a priori
subgroups [19] and is important for feasibility. It does
not preclude exploratory findings, when noted as such,
or limit the span of issues that can be addressed in
future updates.
Phase II: data abstraction and critical appraisal
Data abstraction
Data abstraction is one of the most important and time-
consuming steps of a systematic review [7]. The data collec-
tion instrument (e.g., evidence table, database, web-based
systematic review software) is designed to extract critical
and relevant data from eligible studies, including the details
of the study design and conduct, characteristics of the
population, specific outcomes assessed at specific times,
intervention details, types of comparators, and, when
appropriate to the topic, baseline risk levels of the study
population. These components may be further catego-
rized and summarized during data analysis and synthesis
to allow for investigation of variability in methodological or
clinical factors (see phase III: data analysis and synthesis).
In order to capture specific types of subgroup analyses
conducted in each study, reviewers can make note dur-
ing routine data abstraction of which a priori subpopula-
tions identified in the work plan had subgroup-specific
analyses reported. For the purposes of tracking the types
of subgroup data available in studies, reviewers may
Table 4 Key informant interview sample questions
Are there important advances in research or clinical thinking since [insert year of previous review] that would suggest looking at the same (e.g., age,
sex, risk-defined) and/or other specific subpopulations (e.g., race/ethnicity, co-morbidities, co-interventions)? Which subpopulations are most
important?
What streams of evidence since [insert year of previous review] support your perspective?
Are there key studies we should be aware of in formulating our approach to subpopulations?
Greater benefits from screening can occur in those who are more likely to be undiagnosed, and from intervention in those at higher risk.
Does under-diagnosis vary by age, sex, race/ethnicity or other characteristics? Does absolute risk vary by age, sex, race/ethnicity or other characteristics?
For which subpopulation(s) would benefit from screening and intervention be substantially greater than “average”? Why?
Lesser benefits from screening and intervention can occur in those with competing risks, health states, or limited life expectancy, which reduce the likelihood
of benefit from successful intervention or affect the ability to accurately screen for this condition.
Are there subpopulations that might be substantially less likely to benefit from detection and intervention? Why?
Do the values that patients place on important outcomes (benefits or harms) associated with this topic differ by age, sex, race/ethnicity or other
characteristics? Please be specific.
Based on your answers to these questions, which subpopulations differ substantially enough in the likelihood of benefits (and/or risk of harms)
from screening and intervention of [insert topic] that they may warrant different clinical preventive recommendations?
What criteria would you use to define these clinically relevant subpopulations?
Should this topic be scoped to specifically include a high-risk approach in addition to (or instead of) a general population approach?
What are the validated risk assessment tools that are applicable to this topic?
Are some of the tools better than others for framing a potential high-risk approach to [insert topic]?
Do any tools vary in their applicability to specific subpopulations based on age, sex, race/ethnicity, comorbidities, or other factors?
Is the epidemiological information below [paste data below this question] that we have located to frame this topic complete, current, and
representative of the issues for subpopulations in [insert topic] (i.e., Do the data adequately capture the extent to which death or morbidity from
[insert condition(s)] differ by age, sex, race/ethnicity, or other clinical characteristics?)?
Are there other data sources we should use to frame this topic?
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also make note of which other subpopulations not speci-
fied a priori in the work plan had subgroup analyses
reported.
After initial data abstraction, a working table (Table 6)
can be used to audit the availability of subgroup-specific
analyses in the body of evidence to determine whether it
is feasible or worthwhile to further investigate a priori
subpopulations of interest. Results from the audit
(Table 6—Column 5) provide the rationale for whether
or not to pursue further investigation of subgroup ana-
lysis results and can later be reported in the methods
section of the evidence synthesis report. Within the
working table, it is helpful to track the number of studies
reporting subgroup analyses for the subpopulation of
interest out of the total number of included studies in
the review. As warranted, relevant subpopulation-
specific summary tables can be developed during data
analysis and synthesis.
Critical appraisal
Another essential step in systematic reviews is critical
appraisal of the design and conduct of studies [7, 23]. In
addition to rating the quality of individual studies, asses-
sing the credibility of subgroup analyses reported in
studies is necessary when addressing subpopulation
considerations in a review [8]. Many subgroup-specific
claims made in trial reports are not credible, and key
criteria for credibility should be addressed by the study
authors [24, 25]. These criteria consider type I errors
(spurious findings due to chance or confounding) and
type II errors (failure to detect effects due to power).
General study quality issues (e.g., differential attrition)
may affect the interpretation of subgroup-specific findings.
Similarly, issues that affect subgroup validity may impact
overall ratings of study quality. Subgroup analyses from
poor-quality studies are at high risk of bias regardless of
the credibility of the subgroup analyses.
Systematic reviewers can assess the credibility of sub-
group findings for a priori subpopulations using Tables 7
and 8. Reviewers may consider collecting the data neces-
sary for evaluating the credibility of subgroup analyses
(e.g., a priori specification of analyses, interaction test-
ing) during data abstraction to obviate the need for
another close reading of the article. Using Table 7, for
each study, reviewers can enter a row for each a priori
subpopulation that specifies whether a subgroup effect
was detected (based on interaction testing or point esti-
mates and confidence intervals) and provide assessments
of three domains related to credibility: (1) the likelihood
that positive subgroup effects are spurious, (2) the po-
tential for confounding in a subgroup analysis by another
study variable (relevant to positive or negative subgroup
findings), and (3) whether a trial was powered to detect
subgroup differences, which is primarily relevant to a
finding of no subgroup differences.
Table 8 outlines specific questions about spurious
findings, confounding, and power limitations to assist
reviewers in their credibility assessment of subgroup-
specific analyses for a priori subpopulations. Based on
responses to the questions outlined in Table 8 and
whether observed subgroup effects are biologically
plausible and consistent with evidence from related
studies [8, 24], systematic reviewers can assess the
credibility of each subgroup analysis reported by the
study by judging each of the three domains (spurious,
confounding, power) as very likely, somewhat likely,
unlikely, or unclear—usually due to inadequate report-
ing (Table 7). The spurious effects domain would also
include a “not applicable” option when indicating cred-
ibility assessment for situations when a study does not
detect a difference in subgroup effect.
Reviewers can summarize their study-level subgroup
analysis-specific credibility assessment with an overall
rating (e.g., low, medium, high, or uncertain) that
Table 6 Audit for decision support
Audit of subgroup analysis results
(1)
List all a priori
subpopulations
from work plan
(2)
List all studies conducted in
a subpopulation only
(e.g., older adults, males,
females, diabetics)
(3)
List all studies that reported
subgroup analyses for this
subpopulation
(4)
List all outcomes reported
for each subgroup analysis
for this subpopulation
(5)
Summarize decisions regarding
further investigation of subgroup
analysis results
- Age - Study A (n)
- Study B (n)
- Study C (n)
- Study D (n)
Outcome #1
- Study A
- Study B
Outcome #2
- Study C
- The majority of the studies (x/y) in
the review reported age-related subgroup
analyses. Age-related subgroup results
will be abstracted in a separate table.
- Sex - Study X (men) (n)
- Study Y (men) (n)
- Study Z (women) (n)
- Study A (n)
- Study B (n)
- Study C (n)
Outcome #1
- Study A
- Study B
Outcome #2
- Study C
- The majority of the studies (x/y) in the
review were either conducted in males
or females only, or some type of
sex-related subgroup analysis
was conducted. Sex-related subgroup
results will be abstracted in a separate table.
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incorporates the results of each relevant domain
(Table 7). This overall subgroup analysis credibility
rating represents a summary judgment as to the cred-
ibility of the subgroup-specific analyses conducted in
each study of interest and is therefore taken into con-
sideration within the larger context of the study’s
internal validity (risk of bias) from the critical
appraisal process.
Finally, studies that only enrolled an a priori subpopu-
lation (e.g., 100% female) can be assessed for quality as
part of the routine quality rating process for all studies.
Ancillary reports from included studies reporting rele-
vant subgroup analyses can also be assessed for credibility
using Tables 7 and 8.
Phase III: data analysis and synthesis
Investigating potential sources of heterogeneity at the body
of evidence level
During the data analysis and synthesis phase of system-
atic reviews, reviewers summarize the body of evidence,
appropriately considering differences between studies in
terms of clinical, methodological, and statistical hetero-
geneity (Table 2). Guided by a priori considerations,
reviewers can supplement their systematic consideration
of the similarities and differences across trials in the
body of evidence using the PICOTS (population, inter-
vention, comparator, outcome, timing, and study design)
rubric (Table 9) [26]. Population factors may drive
important clinical heterogeneity based on issues such as
baseline study group risk for intervention-related bene-
fits or harms. In contrast, between-study differences in
the study design or conduct can represent methodo-
logical heterogeneity that is not clinically meaningful,
while intervention and comparator differences may or
may not be clinically relevant. The consistency and vari-
ability in the body of evidence may not be evident when
abstracting data from individual studies, so reviewers
should consider the consistency and variability in all fac-
tors across included studies at this point in the process.
When looking at the body of evidence, reviewers
should consider variability across studies in the baseline
population risk for the primary outcome for which the
intervention is intended since this is one of the primary
drivers of heterogeneity, along with variable risk for
intervention-related harms or presence of competing
risks. Even when an intervention has the same relative
effects across subpopulations, the absolute benefits will
vary, producing much larger beneficial effects in those at
higher baseline risk. Thus, understanding the range of
baseline risks represented across the body of evidence
can be important to interpret findings, whether repre-
sented by absolute or relative effect measures.
Observed variation in population risk (as sometimes
approximated by control group event rates) across
studies may reflect not only different patient popula-
tions with variability in baseline risk among selected
groups but also other factors such as length of study
follow-up [27]. The control group event rate can also
be viewed as a study-level proxy for disease severity,
concomitant treatments, and follow-up duration [28].
Visual inspection of scatter plots or inspection of data
in a spreadsheet to consider the extent of variability
in baseline population risk (or any factor) across the
body of evidence can be a useful initial assessment of
heterogeneity [29].
For example, Fig. 2 shows a scatter plot of control
group event rates for the primary outcome of sexually
transmitted infections by follow-up time [30]. The broad
range of control group rates across 3 to 24 months of
follow-up suggests potential population differences in
baseline risk of sexually transmitted infection. Scatter
plots may also be used to consider the extent of vari-
ability in intervention-related risks (control group event
rates for harms by follow-up time) or the relationship
between baseline risk and absolute benefit (intervention
group event rates by control group event rates).
Reviewers may also use forest plots to investigate
heterogeneity of intervention effects, stratified by popu-
lation type or other important variables for appropriate
time points.
Systematic reviewers consider whether intervention
effects are relatively homogeneous or appear to show
variable effects on primary outcomes, including benefits
and harms. This examination includes, but is not limited
to, using appropriate statistical methods to examine the
consistency and precision of the overall findings. The
Table 7 Credibility assessment of subgroup analyses
Study
name
Sub-
population
Was a subgroup
effect detected?
Likelihood that
subgroup effects
are SPURIOUS
Likelihood of
CONFOUNDING of
subgroup analysis
Likelihood of
inadequate POWER to
detect subgroup differences
Overall ratinga
Study A Ex. Age Indicate
whether the
study found a
difference in
effects for this
subgroup
(i.e., yes, no)
Enter credibility
assessment here
(e.g., very likely,
somewhat likely,
unlikely, unclear,
not applicable)
and any relevant notes
Enter credibility
assessment here
(e.g., very likely,
somewhat likely,
unlikely, unclear)
and any relevant notes
Enter credibility assessment here
(e.g., very likely, somewhat
likely, unlikely, unclear) and
any relevant notes
Enter overall credibility
rating here
(e.g., low, moderate, high,
or uncertain) and any
relevant notes, including
overall quality concerns
for the study
aThe overall rating should reflect consideration of general quality issues in the study.
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Table 8 Framework for assessing credibility of subgroup analyses
Questions to consider for credibility assessment
Likelihood that subgroup effects are
SPURIOUS
MAIN DOMAIN: Was a statistical test for interaction performed and did it indicate effect modification? [24, 53]
The statistical test of subgroup-intervention effect interaction assesses whether the effect differs significantly
between subgroups, rather than only assessing the significance of the intervention effect in one subgroup
or the other [54]. If the p value for the test result is <0.05 (or a more stringent alpha), then the effects
between subgroups are not the same [54]. If there are multiple subgroup-treatment effect interactions,
further statistical analyses are required to confirm whether the effects are independent [54].
When was the subgroup-specific analysis specified?
Determine when the subgroup analyses were specified in the study [24, 54]. An a priori subgroup analysis
is one that is planned and documented before examination of data, preferably in the study protocol,
and ideally includes a hypothesized direction of effect. When reported, this information can often be
found in the methods section of the article. Subgroup treatment effect interactions identified post hoc
must be interpreted with caution. There are no statistical tests of significance that are considered
reliable in this scenario [54].
Was the total number of subgroup analyses limited to a small number of clinically
important questions (i.e., <5)?
This is a study-specific factor, rather than a subgroup-specific one. Subgroup analyses should be limited
to a small number of clinically important questions in each study, and ideally limited to the primary
trial outcome [8, 54]. Sun et al. suggest there should be five or fewer subgroup hypotheses tested [24].
If conducting a large number of subgroup analyses, was the statistical significance threshold adjusted
(e.g., using a lower p value than 0.05)?
This is a study-specific factor. Because the probability of a false positive result is high when a large
number of subgroup analyses are conducted, studies can correct for the inflated false positive rate by
adjusting the significance threshold for their interaction tests [55]. For example, if 10 tests are conducted,
each one could use a 0.005 threshold; if 20 are conducted, each one could use a 0.0025 (these thresholds
were calculated using 0.05/K, where K is the number of independent tests conducted; this equation
ensures that the overall chances of a false positive result are no greater than 5%) [55].
Likelihood of CONFOUNDING of
subgroup analysis
MAIN DOMAIN: Was the subgroup analysis potentially confounded by another study variable?
In subgroup analyses in RCTs, the primary intervention is randomized but the secondary factors defining
subgroups usually are not [56]. Controlling for confounding variables for the secondary factor that
defines a particular subgroup is important when investigators are interested in intervening using the
subgroup factor to increase intervention effect. This information may help judge the concern given to
possible confounding.
Were the intervention arms comparable at baseline for the subgroup of interest?
For example, if the subgroup of interest is sex, the systematic reviewer should try to confirm that males
in the intervention group were comparable to males in the control group. Similarly, females in the
intervention group should be comparable to females in the control group. If the stratified intervention
arms are not comparable at baseline, secondary factors affecting comparability could be confounding
study variables [54].
Was the subgroup variable a characteristic specified at baseline (in contrast with after randomization)?
This ensures that the benefits of randomization are maintained throughout the duration of the study,
and reduces the possibility of confounding [8]. The credibility of subgroup hypotheses based on
post-randomization characteristics can be severely compromised, since any apparent difference in
intervention effect could potentially be explained by the intervention itself or different prognostic
characteristics in subgroups that emerge after randomization [57]. Analyses based on characteristics
that emerge during follow-up violate the principles of randomization and are less valid [26].
Was the subgroup variable a stratification factor at randomization?
Randomization stratified for a priori subpopulations ensures comparable distribution of other characteristics,
including potential confounding factors between subgroups on this factor [24, 54]. Stratified randomization
ensures there is a separate randomization procedure within each subset of participants.
Likelihood of inadequate POWER
to detect subgroup differences
Was the trial powered to detect subgroup differences?
If important subgroup-intervention effect interactions are anticipated, trials should be powered to
detect them reliably [18, 54]. If a trial is underpowered for the main outcomes of interest, it is almost
never adequately powered for a subgroup analysis.
If a study did detect a difference in subgroup effect, then this domain would be assessed as very
unlikely (i.e., that power was inadequate) because the power calculation, which was based on
assumptions such as an estimate of the difference that might exist, is no longer very important
after a significant difference has been revealed. If a study does not detect a difference, then it is
very relevant to assess whether or not the study was underpowered.
To inform judgments made about the evidence, the Grading of Recommendations, Assessment,
Development and Evaluation (GRADE) Working Group suggests that systematic reviewers consider
the optimal information size (OIS) threshold as an additional criterion for adequate precision. OIS is
reached if the total number of patients included in a systematic review is the same or more than
the number of patients generated by a conventional sample size calculation for a single adequately
powered trial [58]. Another potential application of the OIS criterion could be to indicate potential
power issues in important subgroup analyses.
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decision to mathematically combine data depends on
critical judgment [31]. A meta-analysis should only be
conducted when a group of studies is considered homo-
geneous enough in terms of population, interventions,
and outcomes that combining would produce a mean-
ingful summary [7]. The underlying biology should sug-
gest that it is plausible that the magnitude of effect on
the key outcomes should be more or less the same
across the range of patients and interventions [9, 26]. If
meta-analyses are deemed appropriate given the body of
evidence, systematic reviewers should determine appro-
priate statistical methods for meta-analyses and explora-
tions of heterogeneity by first consulting respected
scientific literature and statisticians when necessary. A
detailed discussion of these methods is beyond the scope
of this paper.
Systematic reviewers should formally assess potential
heterogeneity using common statistical approaches to
detect and quantify the degree of heterogeneity (i.e.,
Cochran’s Q test, I2 index) [32, 33]. If reviewers deter-
mine that statistical heterogeneity is present, further
exploration is needed to investigate the potential sources
of heterogeneity. Even when statistical heterogeneity is
not present, a priori factors may still need to be explored
[19], particularly since lack of statistical heterogeneity
does not confirm lack of either clinical or methodo-
logical heterogeneity and statistical tests are generally
considered to be underpowered to detect differences in
subgroup effects [34]. Common approaches for such
investigations include stratified meta-analyses, sensitivity
analyses, and meta-regression [35]. For example, Fig. 3 is
a stratified meta-analysis that provides pooled estimates
for subgroups defined by sleep apnea severity at baseline
Fig. 2 Scatter plot of control group event rates for the primary
outcome of sexually transmitted infections (by longest time points
for each study) [30]
Fig. 3 Forest plot of the effect of continuous positive airway pressure (CPAP) on sleepiness (by obstructive sleep apnea (OSA) severity
at baseline) [6]
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for the effect of continuous positive airway pressure
(CPAP) on sleepiness as measured by the Epworth
Sleepiness Scale [6]. This type of approach provides
information on the degree to which effect sizes differ
between groups of studies and also shows whether a
substantial portion of the statistical heterogeneity was
caused by combining sets of studies into one meta-
analysis. When conducting these types of analyses,
reviewers must consider potential limitations, such as
confounding, inadequate variability, ecological fallacy,
and power [8, 11, 17]. Reviewers may also employ
graphical methods that more broadly identify potential
sources of heterogeneity, being careful to distinguish a
priori from post hoc factors [36].
If meta-analyses are not appropriate given the body of
evidence, reviewers should provide a narrative synthesis
of results, stratified by potential sources of heterogeneity
identified a priori. Systematic reviewers should describe
the individual study results in the context of the appar-
ent heterogeneity (or lack thereof ) in the evidence. In
the absence of formal quantitative synthesis, forest plots
may still be used to display intervention effects, stratified
by population type or other important variables for
appropriate time points, to enhance communication.
Summarizing findings at the subpopulation level
During this phase, reviewers also consider the findings
from relevant subgroup data abstracted during phase II
for each subpopulation. This requires summarizing
whether subgroup-specific findings were available from
individual studies and how credible they were, as well as
their overall coherence across studies. Considered
together with results from examining the body of evidence
for important heterogeneity of intervention effects, these
findings will carry forward to inform judgments by the
guideline developer about the possible need for
subpopulation-specific clinical practice recommendations.
In order to summarize subgroup findings for examin-
ation, systematic reviewers can complete Table 10 for
each a priori subpopulation as appropriate after review-
ing the credibility and availability of subgroup analyses
abstracted across all of the included studies during phase
II. This can be most useful when there are a sufficient
number of studies reporting subgroup-specific or related
analyses for an a priori subpopulation of interest (e.g.,
age-, sex-, or race-specific). If there are few subgroup
analyses reported, text descriptions will usually suffice. If
there are extensive subgroup analyses reported,
reviewers may want to limit the analyses abstracted to
those with at least a moderate overall credibility rating.
Additionally, if reviewers have noted a consistently
reported set of subgroup analyses for an important
subpopulation, or studies targeting that same sub-
population, but the subpopulation was not identified
a priori, it may be appropriate to summarize this
information post hoc in text or in a summary table,
with clear labeling that these represent exploratory
findings.
The synthesis of subpopulation-specific findings con-
siders the (1) volume and credibility of subgroup analyses,
(2) overall coherence of findings, and (3) limitations. The
volume and credibility of subgroup analyses will depend
on the total number of participants represented and the
number of studies reporting subpopulation-specific results
out of the total number of included studies, as well as the
quality of the evidence, judged by threats to credibility of
available subgroup-specific study results and availability
of within-study versus between-study subpopulation
comparisons. The overall coherence of findings can be
assessed by reviewing the consistency of subgroup/sub-
population findings across trials [26], the way sub-
groups are defined, credibility of subgroup analyses,
comparability of studies focused on the specific subpopu-
lations within the body of evidence in terms of PICOTS,
number of studies reporting results for each subgroup by
outcome, and comparison of within-study to between-
study subgroup results. Finally, systematic reviewers
should summarize the limitations of the evidence, includ-
ing potential confounders in individual study subgroup
analyses, potential confounders in the study designs, and
gaps or deficiencies in the subpopulation-specific results.
Reviewers may create summary plots for outcomes of
interest to facilitate considerations of net benefit. These
should always include both benefits and harms. After
transformation to allow statistically combined estimates
to reflect the appropriate direction for a finding (i.e.,
toward benefit or toward harm), summary estimates can
be reflected on a plot (Fig. 4).
Phase IV: reporting and interpretation
Reporting
The value of a systematic review depends on the methods,
findings, and clarity of reporting [37]. Transparency and
consistency are keys to any systematic approach, with
methods and the rationale for decisions and subjective
judgments clearly articulated. As such, systematic re-
viewers should clearly communicate the approach taken
in the review to assess heterogeneity, the types of data
available, judgments about the presence or absence of
important clinical heterogeneity, and appropriate limita-
tions and caveats, as determined by thorough investigation
of data at both the overall body of evidence and subpopu-
lation levels. Findings must be sufficiently clear to inform
judgments about the adequacy of the evidence base for
specific subpopulations and appropriateness of general
population versus subpopulation-specific clinical practice
recommendations, as well as allow for incorporation into
future research considerations. A structured approach to
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reporting facilitates interpretation as well as communica-
tion of data throughout this phase.
A list of elements to include when reporting patient
subpopulation findings in a systematic review is dis-
played in Table 11. Authors should adhere to the
PRISMA (Preferred Reporting Items for Systematic
Reviews and Meta-Analyses) Statement [37] when
reporting a systematic review [19]. We have added ele-
ments specific to subpopulations and heterogeneity of
intervention effects to augment this suggested reporting
approach.
The most informative approach to summarizing the
results of subgroup analyses may be to use the review’s
overall summary (or strength) of evidence table and
stratify the body of evidence by subpopulation within
the appropriate key question(s), especially when the
subgroup data may be the basis for considering a
subpopulation-specific recommendation or clinical
consideration. Using the summary of evidence table
allows reviewers to consistently and transparently
present summary evaluations of each evidence domain
(e.g., consistency, precision, reporting bias, body of
evidence limitations, strength of evidence, applicability)
for important subpopulations [38]. The summary of evi-
dence table can show how the subpopulation-specific
information fits within the overall body of evidence and
organization of the topic. The level of stratification used
for subpopulations depends on the way a topic is concep-
tualized; for example, some topics may be stratified by
intervention type first, with the subpopulation as the sec-
ond order of stratification. For other topics, subpopulation
evidence may only vary for specific domains so would only
be presented for a particular domain (e.g., precision).
For example, a review of screening for obstructive
sleep apnea (OSA) assessed whether benefits of treat-
ment with CPAP differ for subpopulations defined by
OSA severity (among other subpopulation questions
considered) [39]. The review conducted subgroup
meta-analyses by OSA severity categories. One
approach to presenting those findings in an overall
summary of evidence table would be to enter data in
separate rows for the full sample and for each of the
subpopulations, such that treatment with CPAP has a
row for overall findings (for the full population) and
also has rows for each subpopulation (e.g., mild OSA,
moderate OSA, and severe OSA). Such an approach
might be most useful when there are significant
differences for multiple evidence domains between
the overall population and subpopulations (such that
reviewers want to highlight the details of similarities
and differences). The main conclusions of credibility
assessments from phase II would contribute to sub-
population domain entries for quality/risk of bias and
body of evidence limitations. Alternatively, depending
on how the topic was conceptualized and the specific
review findings, the results for subpopulations might
be highlighted (1) only in the applicability domain or
(2) within a single row dedicated to the effects of
treatment with CPAP that first shows effects for the
overall population for each domain and then (below
the overall findings) describes any differences for sub-
populations that were identified and the credibility of
those findings.
Interpretation
Systematic reviewers must consider how to interpret the
overall credibility of subgroup analyses reported by the
studies included in a review. Considerations for judging
the credibility of subpopulation findings at the body of
evidence level include:
 Are the subgroup analyses upon which any
subpopulation analyses are based credible and
consistent across studies and outcomes?
 Do subpopulation findings avoid ecologic fallacy
(i.e., are they based upon meta-regression involving
Fig. 4 Example summary plot for relevant subpopulation-specific outcomes
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only appropriate study-level variables or using
appropriate individual participant data meta-analyses
for patient-level variables)?
 Were the subpopulation analyses in the systematic
review specified a priori in a specific hypothesized
direction?
 Was the total number of subpopulation
investigations in the systematic review limited to a
small number?
 Does statistical analysis suggest chance is an unlikely
basis for subpopulation differences?
 Are subpopulation findings supported by within-
study findings rather than, or in addition to,
between-study comparisons?
 To what extent are subpopulation findings
biologically plausible? [10]
Table 12 provides caveats to assist systematic reviewers
in their interpretation and understanding of the available
subpopulation-specific data. The caveats stress the
importance of caution in the interpretation of subgroup
analyses due to the risk of false positive or false negative
Table 11 Summary of elements to include when reporting a systematic review
Report section Reporting elements
Abstract - Report valid, a priori subgroup or subpopulation findings in the structured abstract.
- Report non-valid or insufficient evidence if it is a critical clinical or policy issue.
Introduction - Summarize the rationale for specific subpopulation considerations, including disease burden and
potential differences in expected harms or benefits from the clinical preventive service,
based on previous research [18].
Methods - Briefly summarize the approach used to identify important subpopulation considerations in the review
(e.g., literature searches, clinical and content expert consultation, and public comments).
- Identify the a priori subpopulations the review addressed and the approaches taken for locating these data.
- Clearly report how subgroups were defined (e.g., by categorical predictors or continuous risk scores) [18].
- Describe methods for abstracting subgroup and related analyses and any quality control processes,
such as dual reviewing extracted data from primary studies [18].
- Describe methods for assessing the credibility of subgroup analyses related to a priori subpopulations
at the study level and for focusing the report on clinically meaningful subpopulation results
in the body of evidence.
- Report methods used to explore heterogeneity of intervention effects [18]. Describe methods
for additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if conducted, indicating
those that were specified a priori [37].
Results - Summarize qualitative heterogeneity of body of evidence at methodological and clinical levels.
- Report all proposed and actual investigations of clinical heterogeneity differentiating prespecified
and post hoc, including all subgroups and outcomes analyzed [18, 19, 61].
- Summarize the frequency of subgroup analyses for a priori subgroups, the credibility of available
subgroup analyses, and overall coherence of findings.
- Report whether within-study results showed statistical evidence of effect modification by baseline
subpopulation or other important characteristics across studies [64].
- Report results of meta-regression or other pooled subpopulation analyses if conducted. Report judgments
or findings of clinical, methodological, or statistical heterogeneity.
- Summarize results of subgroup analyses as absolute risk reductions and relative risk reductions.
- Report any subpopulation differences in rates of serious harms. Report any other factors strongly
associated with these harms [65].
- Any reported results from post hoc subgroups or subpopulations should be labeled exploratory.
Discussion Summary of evidence
- Summarize the main findings for the overall body of evidence and subpopulations of interest [37].
- Report on all a priori subgroups, whether reporting on the absence of data to evaluate, an absence
of detected effect modification (for relative or absolute measures), or detectable effect modification
(on which scale), and its clinical significance.
- Clearly report and distinguish between evidence of no effect, uncertain or incomplete evidence,
or lack of evidence.
- Clearly state when evidence may warrant separate considerations of net benefit in subpopulations.
- Clearly indicate if caution is warranted in applying the average effect for some types of patients,
even if evidence is unavailable or limited.
Limitations
- Summarize limitations of subgroup and subpopulation findings at the study, outcome, and review
levels based on gaps in the evidence.
Future research
- Reference important exploratory findings from post hoc subgroups.
- Provide recommendations on how future research could proceed or build upon results vis-à-vis
important subpopulations.
Conclusions
- Provide a general interpretation of any a priori subpopulation findings in the context of other evidence.
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subgroup effects. Guidelines based on spurious subgroup
analyses could result in subpopulations of patients re-
ceiving inappropriate treatment or being denied benefi-
cial treatment. When data are not definitive, the average
intervention effect is considered the best estimate [40, 41].
Pilot testing confirmed that this phase IV guidance
provides useful caveats to explain the limitations of sub-
population findings and ensures that clear reporting of
subpopulation evidence is not neglected.
Conclusions
In our work conducting systematic reviews for the
USPSTF, we increasingly face the need to provide infor-
mation on how treatment effects differ for some groups
of patients to inform decisions about the appropriate-
ness of subpopulation-specific clinical practice recom-
mendations. Therefore, among a set of reviewers
working across Evidence-based Practice Centers—and in
conjunction with the USPSTF Subpopulation Work-
group—we developed the guidance described in this
paper for addressing subpopulation considerations in
systematic reviews. We would welcome engaging in an
international consortium effort to develop consensus
methods as a next step.
Rigor and comprehensiveness are important to good
systematic review methods, but reviewers have to work
within the time and resource constraints imposed by
those commissioning the review and the guideline
Table 12 Caveats for interpreting and understanding subpopulation-specific data
Availability of subpopulation-specific
data
Caveats
Presence of subpopulation differences
in intervention effects
- When interpreting the presence of subgroup or subpopulation-specific findings, recall that evidence is
usually observational [7]. Consider methodological heterogeneity, confounding and other sources of bias
(e.g., publication, misclassification), magnitude and direction of effect and confidence intervals, and
plausibility of causal relationships. Confounding can lead to spurious or misleading subgroup results,
particularly when subgroup factors are correlated [61].
- When interpreting reported subgroup effects, beware of false positive effects. If multiple subgroup
analyses are conducted, the probability of a false positive finding can be high [55]. Results are more
likely to be real if they are based on a priori analyses because these have prior evidence supporting them.
- When claiming an intervention effect in a subgroup, consider whether appropriate methods (e.g.,
p value adjustment, false discovery rates, Bayesian shrinkage estimates, adjusted confidence intervals,
or internal or external validation methods) were used to account for the number of contrasts examined [18].
Absence of subpopulation differences
in intervention effects
- Subgroup analyses are typically underpowered, thus the risk of false negatives is even higher.
One should be aware of the remaining possibility of false negatives in the absence of relative
intervention effect differences [59].
- Lack of relative intervention effect differences between subgroups may still result in clinically important
variations in absolute benefit due to the impact of differences in baseline risk on absolute intervention effect.
- Lack of difference between subgroups defined on single factors (e.g., age, race/ethnicity) is not sufficient
reasoning that subpopulation differences do not exist. Subgroups defined through multivariable risk
prediction tools are more likely to be clinically applicable and robust, particularly with larger studies.
If a body of evidence has similar multivariable subgroup definitions within studies,
pooling can increase power [66].
- Even without heterogeneity of intervention effects, not everyone who receives a “proven” intervention
will benefit. (For an intervention with a constant 25% relative risk reduction, one-quarter of expected
events will be averted, but 75% of events will still occur despite intervention) [67]. Reminding readers
of this fact and emphasizing absolute effects within overall event rates is informative. Further, this
approach can help clarify why even modest risk of serious harms may, in the end, exert a strong impact
on net benefit calculations for the population as well as for individuals [66].
- When data are not definitive and overall benefits are modest, or overall benefits are moderate but
intervention is costly, retaining the possibility of heterogeneity of intervention effects in the absence
of evidence may be warranted. Consideration of individualized or targeted intervention approaches
may still be applicable for future studies.
- In the absence of compelling evidence, the best estimate is the average intervention effect [40].
Overall - If meta-analyses were conducted, reviewers should consider possible explanations of variations
between clinical and statistical heterogeneity.
- Caution is warranted for definitive subgroup conclusions in the absence of patient-level meta-analysis
or valid study-level methods and replication (or pooling) of within-study subgroup-specific findings
across trials [54].
- Intervention-related risks are substantial (at least for some) and factors that appear to predict increased
risk for serious harms can be related to subpopulations. When serious harms are a key issue, consider
looking for validated risk prediction tools for serious harms to assist in net-benefit considerations,
whether or not reviewed data support subgroup differences [40].
- Data to robustly support subgroup and heterogeneity of intervention evaluations are generally not
available given the current state of clinical trial reporting [68]. As a result, predicting individual effects
occurs less often, even though it is an area of growing interest as the field of precision medicine
develops [18, 69]. Recent recommendations may improve the assessment and reporting of
heterogeneity in clinical trials going forward [59].
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developers or others who will use the results. Therefore,
it is essential to consider whether the value of adding
the subpopulation processes detailed here justifies the
additional time and effort expended. The additional
work necessary to define subpopulations of interest a
priori during initial planning can actually reduce the
time and effort spent in later stages of the review by
limiting subpopulation examinations to those of most
significance to a particular topic. For some topics, early
investigations of subpopulations during topic scoping
may result in a conclusion that further consideration of
subpopulations is not warranted. Systematic investiga-
tion of potential heterogeneity in a body of evidence,
along with quantitative and narrative analysis and syn-
thesis of subgroup data, represents considerable time
and effort and adds a substantial amount of work to the
overall review process. The net value of this process is
therefore contingent on the effectiveness of earlier
phases of the review in identifying the most important
subpopulations for a topic and determining the availability
of credible subgroup data.
Understanding how treatment benefits and harms dif-
fer across patient populations is necessary for optimal
patient care and is increasingly focused on through
“precision medicine”; therefore, methods to incorporate
subpopulation considerations, including credible sub-
group analyses, into systematic reviews and clinical
practice guidelines are increasingly important. Our
proposed approach is intended to allow systematic
reviewers to more robustly and routinely provide infor-
mation about which subpopulations differ enough in
the likelihood of benefits (and/or risk of harms) from a
preventive intervention that they may warrant different
clinical preventive recommendations. Gaps in the evi-
dence on important subpopulations identified by apply-
ing this process in systematic reviews can also suggest
future research needs. Although the processes we
describe here were developed for systematic reviews to
support recommendations made by the USPSTF, they
are likely generalizable to systematic reviews in other
clinical and policy contexts with minimal modification.
We anticipate that this approach will undergo further
refinement with additional use in reviews for the
USPSTF and may require revisions to provide utility to
the producers and users of systematic reviews beyond
the context of the USPSTF and to broaden its applica-
tion to reviews of evidence from non-randomized
studies.
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